Enterprise Value
-27.09M
Cash
57.98M
Avg Qtr Burn
-6.947M
Short % of Float
3.00%
Insider Ownership
38.43%
Institutional Own.
30.03%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LUM-201 (Ibutamoren) Details Pediatric growth hormone deficiency Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
LUM-201 (Ibutamoren) Details Thyroid Eye Disease | Phase 2 Update | |
LUM-201 (Ibutamoren) Details Turner syndrome | Phase 2 Update |